LGALS9 and acute myeloid leukemia: In the current study, treatment with recombinant Gal-9 induced cell death in both AML cell lines and primary patient-derived AML cells, including CD34+ AML stem cells, but not healthy CD34+ cord blood (CB)-derived stem cells.